Seqirus ShipsInfluenza Vaccine

July 15th, 2019 – An Australia-based, worldwide leader in influenza prevention announced it is the first to ship seasonal influenza vaccines to customers in the United States for the 2019-2020 influenza season.   

Seqirus said in a July 15, 2019 press release that it ‘expects to distribute over 50 million doses to the U.S. market this year, with the majority of doses coming from its adjuvanted and cell-based technology platforms.’ 

Seqirus said it will deliver the following influenza products during 2019-2020:

  • AFLURIA® QUADRIVALENT (Influenza Vaccine), an egg-based quadrivalent influenza vaccine
  • FLUAD® (Influenza Vaccine, Adjuvanted), the first-and-only adjuvanted seasonal influenza vaccine developed for people aged 65 and older 
  • FLUCELVAX® QUADRIVALENT (Influenza Vaccine), a cell-based influenza vaccine, available for those aged four and older. FLUCELVAX QUADRIVALENT was manufactured for the 2019/20 influenza season using cell-based candidate vaccine virus (CVV) for all 4 influenza strains recommended by the World Health Organization (WHO)

Additionally, Seqirus said it will distribute Rapivab® (peramivir injection), the only 1-dose intravenous antiviral treatment for acute uncomplicated influenza for people 2 years of age and older. 

"Vaccination can save millions of people," said Gregg Sylvester, M.D., Vice President of Medical Affairs at Seqirus. "In recent years, we have introduced vaccine technology designed to deliver on our commitment to protect people and communities from seasonal influenza." 

The US Centers for Disease Control and Prevention (CDC) encourages annual influenza vaccination for all individuals aged 6 months and older. Because virus transmission to others may occur one day before symptoms develop and up to 5 to 7 days after becoming sick, the disease can be easily transmitted to others.   

Since it takes about 2 weeks after vaccination for antibodies to develop in the body that protects against influenza virus infection, it is best that people get vaccinated to help protect them before influenza begins spreading in their community. 

The CDC estimates that 959,000 people in the United States were hospitalized due to influenza-related complications during the 2017-2018 influenza season. 

Furthermore, a total of 122 influenza-associated pediatric deaths occurring during the 2018-2019 season have been reported to CDC.

 

Payment Notice

Beginning November 1st, 2019, IC/EC will no longer accept 'Invoice Later' at the time of registration. All credit card transactions will confirmed with a email confirmation AND an invoice that can be used for record keeping purposes.

The Source Newsletter

The Network has now been transfered to the National Association for Public Safety Infection Control Officers - NAPSICO.

NAPSICO offers The Source newsletter to members of the Infection Control Network. This bimonthly newsletter comes in two editions to help keep Network members abreast of current infection control issues. One newsletter is tailored for the medical and dental community and the other for law enforcement, fire/rescue, and ambulance service personnel.

For more information contact us at www.NAPSICO.org.

2018 - OSHA/ Infection Control Annual Update Training

Bewildered by what to include in this years infection control training. Wish someone had just written a presentation for you. Look No Further! We have you covered! Follow our scripted presentation. Zika, Ebola and MERS included. 

 Order Here Today

Are Antibacterial Soaps Safe?

Are Antibacterial Soaps Safe? Companies say there's no cause for alarm, but studies suggest they may be dangerous. Now the FDA is preparing to rule. 

Is the quest for clean doing more harm than good?

Read more...